Athersys (ATHX) Osake Kurssi
Athersys Kurssi
Athersysn liikevaihto on supistunut 17,6 % vuodessa viimeisten 19 vuoden aikana 80 000,00 USD:een. Athersysn nettomarginaali −46 883,8 % on laskenut verrattuna −808,1 %:iin muutama vuosi sitten. 7 analyytikosta 6 suosittaa ostoa — kokonaiskonsensus on Osta.
Athersys osakekurssi
Athersys liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Athersys -osakkeesta
The business model of Athersys Inc is focused on the development and commercialization of novel regenerative medicine therapies. As a biotechnology company, Athersys is dedicated to leveraging its proprietary MultiStem® cell therapy platform to treat a range of medical conditions. The company collaborates with strategic partners in both commercial and clinical settings to advance its therapies and expand their potential applications. Athersys aims to address significant unmet medical needs and deliver effective, safe, and cost-efficient treatments for conditions such as stroke, acute respiratory distress syndrome (ARDS), and others. Through innovative research and partnerships, Athersys Inc strives to make a positive impact on patients' lives worldwide.
Athersys Inc is primarily active in the biotechnology industry.
The main competitors of Athersys Inc in the market include companies like Mesoblast Limited, Pluristem Therapeutics Inc, and ReNeuron Group plc. These competitors operate in the field of cell therapy and regenerative medicine, similar to Athersys Inc. Each of these companies aims to provide innovative solutions for treating various medical conditions through the use of stem cells and other advanced technologies.
Athersys Inc has a notable history and background in the biotechnology industry. The company, based in Cleveland, Ohio, was founded in 1995 by Dr. Gil Van Bokkelen. Athersys is focused on developing innovative regenerative therapies utilizing its proprietary stem cell technology platform called MultiStem®. Their research and development efforts have paved the way for potential treatments in various areas, including neurological disorders, inflammatory diseases, and cardiovascular conditions. Athersys has collaborated with leading pharmaceutical companies and academic institutions to advance their therapeutic programs. The company's commitment to pioneering regenerative medicine has positioned Athersys as a key player in the healthcare sector.
Athersys Inc, a leading biotechnology company, has achieved several significant milestones. Notably, they successfully completed Phase 2 clinical trials for their MultiStem® cell therapy in patients with ischemic stroke, demonstrating promising results in terms of safety and efficacy. Moreover, Athersys Inc received Fast Track designation from the FDA for the treatment of acute respiratory distress syndrome (ARDS), reflecting the potential impact of their therapy. Their collaborations with renowned institutions and organizations signify strong partnerships and commitment to advancing regenerative medicine. With continuous innovation and dedication, Athersys Inc is poised to make further strides in developing groundbreaking therapies for various unmet medical needs.
Athersys Inc is primarily present in the United States, focusing on developing their innovative regenerative medicine technologies.
Athersys Inc is committed to delivering innovative therapies that improve patients' lives. The company's corporate philosophy revolves around pioneering stem cell research and developing cutting-edge regenerative medicine technologies. Athersys Inc places immense value on scientific excellence and has a strong focus on collaboration and partnerships to drive advancements in healthcare. By leveraging its proprietary MultiStem® cell therapy platform, Athersys Inc aims to address critical medical needs and provide novel treatment options for conditions such as stroke, acute respiratory distress syndrome (ARDS), and other inflammatory and immune conditions. Through its dedication to scientific expertise and patient-centered approach, Athersys Inc strives to contribute to the betterment of healthcare worldwide.
7 analyytikkoa arvioi tällä hetkellä Athersys-osaketta: 6 suosittaa ostoa, 1 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Athersys-yhtiöltä 2,77 Mrd. USD liikevaihtoa ja −1,56 USD osakekohtaista tulosta.
Athersys-osake (ATHX) on listattuna 5 pörssissä, muun muassa: NASDAQ (ATHX), SIX (Zürich) (4LS.SW), Frankfurt (4LS.F), München (4LS.MU), Düsseldorf (4LS.DU).
Athersys Inc is a biotechnology company focused on developing and commercializing novel therapies for the treatment of diseases. The company is headquartered in Cleveland, Ohio and has subsidiaries in Europe and Asia. Athersys' business model includes three main divisions: regenerative medicine, clinical development, and commercialization. The company has developed a unique technology platform called MultiStem®, which is based on mesenchymal stem cells and has the ability to regulate inflammatory and regenerative processes in the body. The MultiStem technology is currently being studied in clinical trials for the treatment of various indications such as stroke, acute lung injuries, sepsis, and cancer. In the regenerative medicine division, Athersys collaborates closely with research institutions and industry partners to develop new applications for the MultiStem technology. The company has extensive experience in the manufacturing and characterization of mesenchymal stem cells and aims to develop the next generation of cell therapies. Athersys' clinical development division focuses on conducting clinical trials to evaluate the efficacy and safety of MultiStem in various diseases. The company works closely with regulatory authorities such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to obtain approval for MultiStem for the treatment of specific diseases. Finally, Athersys' commercialization division aims to establish MultiStem as an approved drug in the market. Through strategic partnerships with pharmaceutical manufacturers and other companies, the company aims to market MultiStem in different geographic regions and indications. Athersys currently does not have its own product on the market. However, the company collaborates with several pharmaceutical manufacturers and partners to advance the commercialization of MultiStem. Some of Athersys' partners include Pfizer, Healios, Nikon, Chugai, and Helios. In summary, Athersys' business model focuses on using the MultiStem technology for the development of cell-based therapies in regenerative medicine. The company is focused on conducting clinical trials to evaluate the efficacy and safety of MultiStem in the treatment of various diseases. Ultimately, Athersys aims to commercialize MultiStem through partnerships with a wide range of companies and the expansion into different geographic regions.
odotettu liikevaihto Athersys on 2,77 Mrd. USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Athersys on −38,12 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
P/E-suhdetta ei voida laskea Athersys:lle tällä hetkellä.
P/S-suhdetta ei voida laskea Athersys:lle tällä hetkellä.
Athersys:n Eulpool-laatuscore on 2/10.
Athersys:n ISIN on US04744L1061. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Athersys:n WKN on A0M085. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Athersys:n ticker on ATHX. Tämä pörssinoteeraus käytetään Athersys-osakkeiden kauppaan pörssissä.
Athersys osake
Athersys vertaisryhmä
Athersys Ticker
Athersys FIGI
Kaikki tunnusluvut ja syvällinen analyysi Athersys:sta
Meidän osakeanalyysimme Athersys-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Athersys:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: